Analyst firms · H.C. Wainwright · ZYME
H.C. Wainwright ZYME price target and rating history
Zymeworks Inc. (ZYME) · Health Care
H.C. Wainwright rates Zymeworks Inc. (ZYME) Buy with a $55 price target, as of its latest action on Aug 26, 2026. It has published 5 rating actions on ZYME since August 2021, including 1 upgrade and 1 downgrade. Across 5 firms with a ZYME price target in the last 12 months, the median target is $33. H.C. Wainwright's $55 is 67% above that.
- Current rating
- Buy
- Price target
- $55
- Median target, all firms
- $33
- Actions on ZYME
- 5
H.C. Wainwright price target on ZYME
Every H.C. Wainwright rating on ZYME
- Aug 26, 2026
- Oct 14, 2025
- Jan 4, 2023
- Nov 1, 2022
- Aug 5, 2021
How other firms rate ZYME
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| TD Cowen | Buy | $34 | Sep 29, 2026 |
| Wolfe Research | Outperform | Sep 17, 2026 | |
| H.C. Wainwright | Buy | $55 | Aug 26, 2026 |
| Truist Securities | Buy | $28 | Jun 9, 2026 |
| Wells Fargo | Overweight | $33 | Dec 12, 2025 |
| Citizens JMP | Mkt Outperform | $32 | Dec 3, 2025 |
Questions about H.C. Wainwright and ZYME
- What is H.C. Wainwright's price target for ZYME?
- H.C. Wainwright's latest stated price target for Zymeworks Inc. (ZYME) is $55, from its action on Aug 26, 2026.
- What is H.C. Wainwright's rating on ZYME?
- H.C. Wainwright rates ZYME Buy, a bullish rating, as of Aug 26, 2026.
- When did H.C. Wainwright last change its view on ZYME?
- On Aug 26, 2026, H.C. Wainwright raises its price target to $55 from $51, keeps Buy.
- How does H.C. Wainwright's ZYME target compare with other analysts?
- Across 5 firms with a ZYME price target in the last 12 months, the median target is $33. H.C. Wainwright's $55 is 67% above that.
More ZYME rating histories
All H.C. Wainwright ratingsZYME news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.